BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gómez-de León A, Villela-martínez LM, Yáñez-reyes JM, Gómez-almaguer D. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. Expert Review of Hematology 2020;13:461-70. [DOI: 10.1080/17474086.2020.1750361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Al-Tamimi M, Qiao J, Gardiner EE. The utility of platelet activation biomarkers in thrombotic microangiopathies. Platelets 2022;:1-9. [PMID: 35287530 DOI: 10.1080/09537104.2022.2026912] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tripiciano C, Zangari P, Montanari M, Leone G, Massella L, Garaboldi L, Massoud M, Lancellotti S, Strocchio L, Manno EC, Palma P, Corsetti T, Luciani M. Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy. Front Pediatr 2021;9:743206. [PMID: 34796152 DOI: 10.3389/fped.2021.743206] [Reference Citation Analysis]
3 Galindo-Calvillo CD, Rodríguez-Roque CS, Gómez-De León A, Tarín-Arzaga L, Gómez-Almaguer D. Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review. Transfus Apher Sci 2021;60:103107. [PMID: 33714651 DOI: 10.1016/j.transci.2021.103107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]